Abstract:It is widely accepted that Type 1 diabetes is a complex disease. Genetic predisposition and environmental factors favour the triggering of autoimmune responses against pancreatic β-cells, eventually leading to β-cell destruction. Over 40 susceptibility loci have been identified, many now mapped to known genes, largely supporting a dominant role for an immune-mediated pathogenesis. This role is also supported by the identification of several islet autoantigens and antigen-specific responses in patients with recent onset diabetes and subjects with pre-diabetes. Increasing evidence suggests certain viruses as a common environmental factor, together with diet and the gut microbiome. Inflammation and insulin resistance are emerging as additional cofactors, which might be interrelated with environmental factors. The heterogeneity of disease progression and clinical manifestations is likely a reflection of this multifactorial pathogenesis. So far, clinical trials have been mostly ineffective in delaying progression to overt diabetes in relatives at increased risk, or in reducing further loss of insulin secretion in patients with new-onset diabetes. This limited success may reflect, in part, our incomplete understanding of key pathogenic mechanisms, the lack of truly robust biomarkers of both disease activity and β-cell destruction, and the inability to assess the relative contributions of various pathogenic mechanisms at various time points during the course of the natural history of Type 1 diabetes. Emerging data and a re-evaluation of histopathological, immunological and metabolic findings suggest the hypothesis that unknown mechanisms of β-cell dysfunction may be present at diagnosis, and may contribute to the development of hyperglycaemia and clinical symptoms.

Type 1 diabetes mellitus as a disease of the β-cell (do not blame the immune system?)

The β-Cell in Type 1 Diabetes Pathogenesis: A Victim of Circumstances or an Instigator of Tragic Events?

Presumption of innocence for beta cells: why are they vulnerable autoimmune targets in type 1 diabetes?

Innate Immunity in Type 1 Diabetes

β cell ER stress and the implications for immunogenicity in type 1 diabetes

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

Rebalancing the Immune System to Treat Type 1 Diabetes

Type 1 diabetes: pathogenesis and prevention

Revisiting the Antigen-Presenting Function of β Cells in T1D Pathogenesis

Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus

Advances in the Cellular Immunological Pathogenesis of Type 1 Diabetes.

Type 1 diabetes: immune pathology and novel therapeutic approaches

Immune and Pancreatic β Cell Interactions in Type 1 Diabetes

The immunology of type 1 diabetes

Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response

Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive

Cross Talk between β Cells and Immune Cells: What We Know, What We Think We Know, and What We Should Learn

The Pathogenesis of Type 1 Diabetes

The multiple origins of Type 1 diabetes

The role of islet autoantigen-specific T cells in the onset and treatment of type 1 diabetes mellitus

Autoimmune interactions between the HLA-DQβ157 polymorphism, T cell receptors, and microbial mimics of insulin in type 1 diabetes